Review of Its Pharmacodynamic and Pharmacokinetic Properties , and Therapeutic Efficacy in the Treatment of Hypertension

Various sections of the manuscript rev iewed by: B. Jarrott, Clinical Pharmacology and Therapeutics Unit, Department of Medicine, University of Melbourne, Heidelberg, Victoria, Australia; W. Kirch, Medizinische Klinik u. Poliklinik der Universitatsklinik (GHS), Essen, West Germany; A.D. Strutlrers, Department ofClinical Pharmacology, University of London Royal Postgraduate Medical School, Hammersmith Hospital, London, England; P.A. van Zwieten, Division of Pharmacotherapy, University of Amsterdam, Amsterdam, The Netherlands.

[1]  J. Hauger-Klevene,et al.  Effects of guanfacine on growth hormone, prolactin, renin, lipoproteins and glucose in essential hypertension. , 1986, The American journal of cardiology.

[2]  J. Fillingim,et al.  Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension. , 1986, The American journal of cardiology.

[3]  J. Rosenthal.  Hemodynamic and endocrine responses to guanfacine in normotensive volunteers and hypertensive patients. , 1986, The American journal of cardiology.

[4]  Adesh K. Jain,et al.  Clonidine and guanfacine in hypertension , 1985, Clinical pharmacology and therapeutics.

[5]  J. Kapocsi,et al.  Effects of clonidine and guanfacine in essential hypertension , 1984, Clinical pharmacology and therapeutics.

[6]  A. Struthers,et al.  Effect of centrally acting alpha-adrenergic agonists on sympathetic nervous system function in humans. , 1984, Hypertension.

[7]  M. Caron,et al.  Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. , 1984, The New England journal of medicine.

[8]  T. Hedner,et al.  Guanfacine in essential hypertension: Effects during rest and isometric exercise , 1984, Clinical pharmacology and therapeutics.

[9]  P. Jerie,et al.  Long-term efficacy and tolerance of the antihypertensive agent guanfacine. , 1984, International journal of clinical pharmacology, therapy and toxicology.

[10]  R. Joshi,et al.  A Comparative Study of A New Alpha‐Adrenoceptor Agonist, Guanfacine and Alpha‐Methyldopa in The Treatment of Hypertension , 1984, The British journal of clinical practice.

[11]  P. Timmermans,et al.  Cardiovascular effects of withdrawal of some centrally acting antihypertensive drugs in the rat , 1983 .

[12]  L. Hansson.  CLINICAL ASPECTS OF BLOOD PRESSURE CRISIS DUE TO WITHDRAWAL OF CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS , 1983 .

[13]  F. Boomsma,et al.  Regulation of α- and β-adrenoceptor responsiveness: Studies in patients with chronic autonomic failure. , 1983 .

[14]  P. Brummelen,et al.  THE INFLUENCE OF GUANFACINE ON BLOOD PRESSURE AND LUNG FUNCTION IN HYPERTENSIVE PATIENTS WITH CHRONIC OBSTRUCTIVE LUNG DISEASE , 1983 .

[15]  J. Reid,et al.  CENTRAL α2‐ADRENOCEPTORS AND BLOOD PRESSURE REGULATION IN MAN: STUDIES WITH GUANFACINE (BS100‐141) AND AZEPEXOLE (BHT 933) , 1983 .

[16]  L. Pichler,et al.  α1α2 selectivity ratio in a series of agonists and their relation to pre/postsynaptic activity ratios , 1983 .

[17]  E. Cagliero,et al.  Reduced Glucose Tolerance after Guanfacine in Normal and Obese Subjects , 1983, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[18]  C. Gennari,et al.  Comparison of Effects of Guanfacine and Clonidine on Blood Pressure, Heart Rate, Urinary Catecholamines, and Cyclic Nucleotides During and After Administration to Patients with Mild to Moderate Hypertension , 1983, Journal of cardiovascular pharmacology.

[19]  F. Markwardt,et al.  Characterisation of postjunctional α-adrenoceptors in isolated human femoral veins and arteries , 1983, Naunyn-Schmiedeberg's Archives of Pharmacology.

[20]  P. Timmermans,et al.  Precipitation by Yohimbine of the Withdrawal Syndromes of Clonidine, Guanfacine, and Methyldopa in the Spontaneously Hypertensive Rat , 1983, Journal of cardiovascular pharmacology.

[21]  J. Reid,et al.  COMPARISON OF THE ACTIONS OF CENTRALLY AND PERIPHERALLY ADMINISTERED CLONIDINE AND GUANFACINE IN THE RABBIT: INVESTIGATION OF THE DIFFERENCES , 1982, British journal of pharmacology.

[22]  M. Valenzuela,et al.  Guanfacina en hipertension arterial primaria : estudio clinico abierto a largo plazo , 1982 .

[23]  I. Lipinska,et al.  High-density lipoproteins and atherosclerosis. , 1982, The New England journal of medicine.

[24]  W. Kirch,et al.  Pharmacokinetics of guanfacine in patients undergoing haemodialysis , 1982, European Journal of Drug Metabolism and Pharmacokinetics.

[25]  J. Holló,et al.  Long-term antihypertensive therapy with guanfacine. , 1982, International journal of clinical pharmacology, therapy and toxicology.

[26]  O. Brodde,et al.  GTP regulates binding of agonists to alpha 2-adrenergic receptors in human platelets. , 1982, Archives internationales de pharmacodynamie et de therapie.

[27]  S. Imai,et al.  [Effects of guanfacine on pre- and postsynaptic alpha-adrenoceptors studied in comparison with those of clonidine]. , 1982, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[28]  E. Myhre,et al.  Clinical Pharmacokinetics of Methyldopa , 1982, Clinical pharmacokinetics.

[29]  G. Kleinberger,et al.  Duration of the hypotensive effect of guanfacine. , 1982, International journal of clinical pharmacology, therapy and toxicology.

[30]  P. Timmermans,et al.  Guanfacine and clonidine: antihypertensive and withdrawal characteristics after continuous infusion and its interruption in the spontaneously hypertensive and normotensive rat , 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  W. Louis,et al.  [3H]‐GUANFACINE: A RADIOLIGAND THAT SELECTIVELY LABELS HIGH AFFINITY α2‐ADRENOCEPTOR SITES IN HOMOGENATES OF RAT BRAIN , 1982, British journal of pharmacology.

[32]  J. Hauger-Klevene,et al.  Blood Pressure and Prolactin: Effects of Guanfacine Three‐Year Follow‐Up Study , 1981, Hypertension.

[33]  P. Jerie,et al.  Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy. , 1981, International journal of clinical pharmacology, therapy, and toxicology.

[34]  C. Zamboulis,et al.  Effects of single and multiple doses of guanfacine in essential hypertension , 1980, Clinical pharmacology and therapeutics.

[35]  W. Louis,et al.  Selectivity of a series of clonidine-like drugs for α 1 and α 2 adrenoceptors in rat brain , 1980, Neuroscience Letters.

[36]  J. Rauh,et al.  Hämodynamische Untersuchungen mit dem neuen Antihypertensivum Guanfacin: Kreislaufverhalten bei Hypertonikern im Akut- und Langzeitversuch, in Ruhe und unter Belastung , 1980 .

[37]  W. Braun,et al.  The Influence of Renal Function on Plasma Concentration, Urinary Excretion and, Antihypertensive Effect of Guanfacine , 1980, Clinical pharmacokinetics.

[38]  F. Rengo,et al.  Long term comparative study of guanfacine and alpha-methyldopa in essential hypertension. , 1980, Archives internationales de pharmacodynamie et de therapie.

[39]  J. Rosenthal.  Effect of guanfacine on blood pressure and renin activity in hypertensive patients. , 1980, British journal of clinical pharmacology.

[40]  W. Patsch,et al.  Guanfacine and glucose metabolism. , 1980, British journal of clinical pharmacology.

[41]  J. Rosenthal,et al.  Haemodynamics in hypertensive patients before and during guanfacine treatment. , 1980, British journal of clinical pharmacology.

[42]  J. Kiechel.  Pharmacokinetics and metabolism of guanfacine in man: a review. , 1980, British journal of clinical pharmacology.

[43]  W. Schoeppe,et al.  Guanfacine in essential hypertension: effect on blood pressure, plasma noradrenaline concentration and plasma renin activity. , 1980, British journal of clinical pharmacology.

[44]  I. Lancranjan.  Effect of guanfacine on pituitary hormones in man. , 1980, British journal of clinical pharmacology.

[45]  W. Kirch,et al.  Antihypertensive effect of guanfacine: a double-blind cross-over trial compared with clonidine. , 1980, British journal of clinical pharmacology.

[46]  C. Dollery,et al.  Centrally acting drugs in antihypertensive therapy. , 1980, British journal of clinical pharmacology.

[47]  E. Philipp.  Guanfacine in the treatment of hypertension due to pre-eclamptic toxaemia in thirty women. , 1980, British journal of clinical pharmacology.

[48]  E. Heidbreder,et al.  Effect of guanfacine on vigilance. , 1980, British journal of clinical pharmacology.

[49]  L. Spallone,et al.  Hypotensive effect of guanfacine in essential hypertension: a comparison with clonidine. , 1980, British journal of clinical pharmacology.

[50]  K. Stumpe,et al.  Evaluation of long-term treatment of essential hypertension with guanfacine. , 1980, British journal of clinical pharmacology.

[51]  W. Braun,et al.  Elimination of guanfacine in patients with normal and impaired renal function. , 1980, British journal of clinical pharmacology.

[52]  P. Manhem,et al.  Blood pressure, heart rate, catecholamines and plasma renin activity following institution and withdrawal of guanfacine treatment in moderate hypertension. , 1980, British journal of clinical pharmacology.

[53]  A. Heidland,et al.  Comparative studies of guanfacine and methyldopa. , 1980, British journal of clinical pharmacology.

[54]  P. Jerie.  Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine. , 1980, British journal of clinical pharmacology.

[55]  G. Hitzenberger,et al.  Haemodynamic effects of guanfacine. , 1980, British journal of clinical pharmacology.

[56]  H. M. Brecht,et al.  Differences in psychic performance with guanfacine and clonidine in normotensive subjects. , 1980, British journal of clinical pharmacology.

[57]  P. Jerie.  Clinical experience with guanfacine in long-term treatment of hypertension. , 1980, British journal of clinical pharmacology.

[58]  J. Gillette.  Biotransformation of drugs during aging. , 1979, Federation proceedings.

[59]  M. Safar,et al.  Guanfacine kinetics in patients with hypertension , 1979, Clinical pharmacology and therapeutics.

[60]  G. Stokes,et al.  Studies in the rat on the haemodynamic overshoot response to withdrawal of guanfacine or clonidine treatment , 1979, Clinical and experimental pharmacology & physiology.

[61]  M. Guerret,et al.  Determination of guanfacine in biological fluids by electron-capture GLC. , 1979, Journal of pharmaceutical sciences.

[62]  I. Lancranjan,et al.  Inhibitory effect of guanfacine, a central alpha-adrenoceptor agonist, on prolactin secretion stimulated by insulin-induced hypoglycemia. , 1978, The Journal of clinical endocrinology and metabolism.

[63]  J. Halter,et al.  Induction of Defective Insulin Secretion and Impaired Glucose Tolerance by Clonidine Selective Stimulation of Metabolic Alpha-adrenergic Pathways , 1978, Diabetes.

[64]  W. Kirch,et al.  Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine. , 1978, International journal of clinical pharmacology and biopharmacy.

[65]  I. Lancranjan,et al.  New evidence for growth hormone modulation by the α-adrenergic system in man , 1977 .

[66]  C. Dollery,et al.  Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. , 1977, Clinical science and molecular medicine.

[67]  C. Dollery,et al.  CLONIDINE WITHDRAWAL IN HYPERTENSION Changes in Blood-pressure and Plasma and Urinary Noradrenaline , 1977, The Lancet.

[68]  E. Raftery,et al.  Blood pressure and heart rate and withdrawal of antihypertensive drugs. , 1977, British medical journal.

[69]  W. Ganong,et al.  Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs , 1976, Neuroscience.

[70]  S. Duncan,et al.  The effects of atenolol (tenormin) and methyldopa on simple tests of central nervous function. , 1975, British journal of clinical pharmacology.

[71]  G. Scholtysik,et al.  Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141). , 1975, Arzneimittel-Forschung.

[72]  S. Julius,et al.  Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. , 1973, American heart journal.

[73]  S. Hoobler,et al.  Comparison of clonidine and methyldopa on blood pressure and side effects in hypertensive patients. , 1972, American heart journal.

[74]  P. V. van Zwieten,et al.  The central hyperglycaemic effect of clonidine. , 1971, European journal of pharmacology.

[75]  J. Giudicelli,et al.  Centrally mediated decrease in sympathetic tone induced by 2(2,6-dichlorophenylamino)-2 imidazoline (S.T. 155, Catapresan). , 1967, European journal of pharmacology.

[76]  R. N. Brogden,et al.  Low-Dose Clonidine: A Review of its Therapeutic Efficacy in Migraine Prophylaxis , 2012, Drugs.

[77]  J. Reid,et al.  Guanfacine: effects of long-term treatment and withdrawal. , 1980, British journal of clinical pharmacology.

[78]  Editor-in-Chief R. Seifert,et al.  Naunyn-Schmiedeberg's archives of pharmacology , 2005, Klinische Wochenschrift.

[79]  N. Andén,et al.  Different alpha-adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[80]  C. Dollery,et al.  Evidence for a peripheral component in the sympatholytic actions of clonidine and guanfacine in man , 2004, European Journal of Clinical Pharmacology.

[81]  A. Jäättelä,et al.  Comparison of BS 100-141 and clonidine as antihypertensive agents , 2004, European Journal of Clinical Pharmacology.

[82]  J. Hauger-Klevene,et al.  Improvement of glucose tolerance in hypertensive diabetic patients treated with guanfacine one year , 2004, European Journal of Clinical Pharmacology.

[83]  J. Chalmers,et al.  Double-blind trial comparing guanfacine and methyldopa in patients with essential hypertension , 2004, European Journal of Clinical Pharmacology.

[84]  J. Reid,et al.  Withdrawal of guanfacine after long-term treatment in essential hypertension , 2004, European Journal of Clinical Pharmacology.

[85]  J. Fillastre,et al.  Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure , 2004, European Journal of Clinical Pharmacology.

[86]  M. Velasco,et al.  Systemic and cardiac haemodynamic interactions between guanfacine and hydrallazine in hypertensive patients , 2004, European Journal of Clinical Pharmacology.

[87]  A. Verniory,et al.  Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension. , 1985, Acta Cardiologica.

[88]  M. Farooki,et al.  Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension. , 1985, Clinical therapeutics.

[89]  A. Struthers,et al.  Peripheral α2 Adrenoceptor Stimulation Contributes to the Sympatholytic Effect of Guanfacine in Humans , 1985, Journal of cardiovascular pharmacology.

[90]  J. Hauger-Klevene.  Hypolipaemic effect of guanfacine: Two years' follow-up , 1984 .

[91]  C. Feldstein,et al.  Hemodynamic effects of guanfacine in essential hypertension. , 1984, Clinical Therapeutics.

[92]  J. Hauger-Klevene.  Guanfacine-induced withdrawal syndrome: effect of labecetol , 1983 .

[93]  B. Magnani,et al.  Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa. , 1983, International journal of clinical pharmacology research.

[94]  M. Meregalli,et al.  Effects during and after treatment of hypertension with guanfacine: A controlled clinical trial in comparison with alpha-methyldopa , 1983 .

[95]  J. Hauger-Klevene,et al.  Long-term treatment of essential hypertension with guanfacine: Effect on cardiovascular complications, renin and prolactin , 1982 .

[96]  Y. Michotte,et al.  Low dose guanfacine once-a-day for the treatment of hypertension in general practice: A multi-centre pilot study , 1982 .

[97]  J. Reid,et al.  Studies on clonidine and guanfacine withdrawal after short term treatment in the rat. , 1982, Archives internationales de pharmacodynamie et de therapie.

[98]  D. Beevers,et al.  Guanfacine: a new centrally-acting antihypertensive agent. , 1981, Pharmatherapeutica.

[99]  H. Togashi,et al.  Effects of abrupt cessation of treatment with clonidine and guanfacine on blood pressure and heart rate in spontaneously hypertensive rats. , 1981, Clinical and experimental hypertension.

[100]  S. Lochaya,et al.  Antihypertensive effect of BS 100-141, a new central acting antihypertensive agent. , 1980, American heart journal.

[101]  P. V. van Zwieten.  Pharmacology of centrally acting hypotensive drugs. , 1980, British Journal of Clinical Pharmacology.

[102]  P. Boer,et al.  Clonidine withdrawal. Mechanism and frequency of rebound hypertension. , 1979, British journal of clinical pharmacology.

[103]  G. Stokes,et al.  Comparative haemodynamic effects of clonidine and guanfacine. , 1978, Archives internationales de pharmacodynamie et de therapie.

[104]  J. Reid,et al.  2715 – COMPARISON OF CARDIOVASCULAR AND OTHER EFFECTS OF CLONIDINE AND BS 100-141 , 1978 .

[105]  T. Betts,et al.  The psychomotor effects of atenolol and other antihypertensive agents. , 1977, Postgraduate medical journal.

[106]  E. Raftery,et al.  The over-shoot phenomenon on withdrawal of clonidine therapy. , 1976, Postgraduate medical journal.

[107]  G. Scholtysik,et al.  Pharmacology of BS 100-141, a centrally acting antihypertensive drug. , 1975, Clinical and experimental pharmacology & physiology.